Kenvue (NYSE:KVUE) Now Covered by Analysts at Jefferies Financial Group

Research analysts at Jefferies Financial Group began coverage on shares of Kenvue (NYSE:KVUE) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group’s price target points to a potential upside of 17.29% from the company’s current price.

KVUE has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft upped their price objective on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Piper Sandler raised their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday. Citigroup lowered their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, UBS Group lifted their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $22.10.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.02 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The stock has a market cap of $44.08 billion, a price-to-earnings ratio of 29.51, a PEG ratio of 2.92 and a beta of 1.40. The business’s 50 day moving average is $21.02 and its 200 day moving average is $19.99. Kenvue has a 12-month low of $17.67 and a 12-month high of $23.55.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter last year, the firm earned $0.32 EPS. The company’s quarterly revenue was down .3% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue will post 1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kenvue

Several institutional investors have recently made changes to their positions in KVUE. Marathon Capital Management grew its position in shares of Kenvue by 0.3% in the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after purchasing an additional 514 shares in the last quarter. Manchester Capital Management LLC increased its position in shares of Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares during the period. Poehling Capital Management INC. increased its position in shares of Kenvue by 0.5% during the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after buying an additional 547 shares during the period. Pathway Financial Advisers LLC lifted its holdings in shares of Kenvue by 12.0% in the second quarter. Pathway Financial Advisers LLC now owns 5,131 shares of the company’s stock worth $93,000 after buying an additional 549 shares in the last quarter. Finally, Tradition Wealth Management LLC boosted its position in shares of Kenvue by 2.8% in the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock valued at $458,000 after acquiring an additional 575 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.